These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 31738083

  • 1. Preparation and in vivo evaluation of a highly skin- and nail-permeable efinaconazole topical formulation for enhanced treatment of onychomycosis.
    Lee BC, Pangeni R, Na J, Koo KT, Park JW.
    Drug Deliv; 2019 Dec; 26(1):1167-1177. PubMed ID: 31738083
    [Abstract] [Full Text] [Related]

  • 2. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
    Sugiura K, Sugimoto N, Hosaka S, Katafuchi-Nagashima M, Arakawa Y, Tatsumi Y, Jo Siu W, Pillai R.
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
    [Abstract] [Full Text] [Related]

  • 3. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
    Sakamoto M, Sugimoto N, Kawabata H, Yamakawa E, Kodera N, Pillai R, Tatsumi Y.
    J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
    [Abstract] [Full Text] [Related]

  • 4. Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach.
    Kircik LH.
    J Drugs Dermatol; 2014 Dec; 13(12):1457-61. PubMed ID: 25607788
    [Abstract] [Full Text] [Related]

  • 5. Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
    Bhatt V, Pillai R.
    J Pharm Sci; 2015 Jul; 104(7):2177-82. PubMed ID: 25940933
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
    Elewski BE, Pollak RA, Pillai R, Olin JT.
    J Drugs Dermatol; 2014 Nov; 13(11):1394-8. PubMed ID: 25607708
    [Abstract] [Full Text] [Related]

  • 8. Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis.
    Kawai M.
    Med Mycol J; 2019 Nov; 60(3):71-74. PubMed ID: 31474693
    [Abstract] [Full Text] [Related]

  • 9. Antidermatophyte activity and PK/PD of ME1111 in a guinea pig model of tinea corporis.
    Takei-Masuda N, Nagira Y, Kubota-Ishida N, Chikada T, Tabata Y, Maebashi K.
    J Antibiot (Tokyo); 2024 Aug; 77(8):533-539. PubMed ID: 38769156
    [Abstract] [Full Text] [Related]

  • 10. Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis.
    Matsuda Y, Sugiura K, Hashimoto T, Ueda A, Konno Y, Tatsumi Y.
    PLoS One; 2016 Aug; 11(7):e0159661. PubMed ID: 27441843
    [Abstract] [Full Text] [Related]

  • 11. Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis.
    Adigun CG, Vlahovic TC, McClellan MB, Thakker KD, Klein RR, Elstrom TA, Ward DB.
    J Drugs Dermatol; 2016 Sep 01; 15(9):1116-20. PubMed ID: 27602975
    [Abstract] [Full Text] [Related]

  • 12. A comparative study between two antifungal agents, Luliconazole and Efinaconazole, of their preventive effects in a Trichophyton-infected guinea pig onychomycosis model.
    Nakamura A, Hirakawa S, Nagai H, Inagaki K.
    Med Mycol; 2021 Mar 04; 59(3):289-295. PubMed ID: 33539539
    [Abstract] [Full Text] [Related]

  • 13. Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.
    Monti D, Mazzantini D, Tampucci S, Vecchione A, Celandroni F, Burgalassi S, Ghelardi E.
    Antimicrob Agents Chemother; 2019 Oct 04; 63(10):. PubMed ID: 31332076
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
    Hafeez F, Hui X, Selner M, Rosenthal B, Maibach H.
    Drug Dev Ind Pharm; 2014 Jun 04; 40(6):838-44. PubMed ID: 23600655
    [Abstract] [Full Text] [Related]

  • 16. Topical application of acidified nitrite to the nail renders it antifungal and causes nitrosation of cysteine groups in the nail plate.
    Finnen MJ, Hennessy A, McLean S, Bisset Y, Mitchell R, Megson IL, Weller R.
    Br J Dermatol; 2007 Sep 04; 157(3):494-500. PubMed ID: 17627796
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.
    Tatsumi Y, Yokoo M, Senda H, Kakehi K.
    Antimicrob Agents Chemother; 2002 Dec 04; 46(12):3797-801. PubMed ID: 12435679
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole.
    Vlahovic TC, Coronado D, Chanda S, Merchant T, Zane LT.
    J Drugs Dermatol; 2016 Jan 04; 15(1):89-94. PubMed ID: 26741386
    [Abstract] [Full Text] [Related]

  • 19. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
    McAuley WJ, Jones SA, Traynor MJ, Guesné S, Murdan S, Brown MB.
    Eur J Pharm Biopharm; 2016 May 04; 102():178-84. PubMed ID: 26969264
    [Abstract] [Full Text] [Related]

  • 20. In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis.
    Kubota-Ishida N, Takei-Masuda N, Kaneda K, Nagira Y, Chikada T, Nomoto M, Tabata Y, Takahata S, Maebashi K, Hui X, Maibach HI.
    Antimicrob Agents Chemother; 2018 Jan 04; 62(1):. PubMed ID: 29084749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.